<!-- mobian-agent-page publisher="dailydev" canonical="https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv" -->

---
title: It’s biotech, but it works almost like programmable software
description: Researchers at Peking University engineered a bifunctional molecule that both destroys PD-L1 (the protein tumors use to suppress nearby immune cells) and...
canonical: https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv
twitter:card: summary_large_image
twitter:site: @dailydotdev
og:type: website
og:site_name: daily.dev
og:title: It’s biotech, but it works almost like programmable software | daily.dev
og:description: Researchers at Peking University engineered a bifunctional molecule that both destroys PD-L1 (the protein tumors use to suppress nearby immune cells) and...
og:url: https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv
og:image: https://api.daily.dev/og/posts/NUw8IrQzv.png
og:image:alt: It’s biotech, but it works almost like programmable software
og:image:width: 1200
og:image:height: 630
og:locale: en
---

> ## Documentation Index
> Fetch the complete documentation index at: https://daily.dev/llms.txt
> Use this file to discover all available pages before exploring further.

# It’s biotech, but it works almost like programmable software

**[Tiff In Tech](https://daily.dev/sources/tiffintech)** · 1 min read · 0 upvotes · 0 comments

## Summary

Researchers at Peking University engineered a bifunctional molecule that both destroys PD-L1 (the protein tumors use to suppress nearby immune cells) and delivers a viral protein fragment that flags the cancer cell for immune attack, effectively turning a killed tumor cell into a localized vaccine. The molecule activates only inside the tumor rather than systemically. In mouse studies, four doses injected directly into tumors every three days showed efficacy, and results held up in lab-grown tissue from real patient tumors, though human clinical trials have not yet been conducted.

## Full article

daily.dev links to this article rather than hosting it. Read it at the original source: <https://www.youtube.com/watch?v=GgE6hmHsYnM>

## Questions this post answers

### What is PDL1 and why do tumors use it to evade the immune system

PDL1 is a protein displayed on tumor cell surfaces that signals nearby immune cells to stand down, allowing the tumor to avoid attack even as it grows. Researchers at Peking University built a targeted protein degrader designed to find and destroy PDL1, removing that suppressive signal so the immune system can respond.

_daily.dev surfaces emerging biotech mechanisms like this for engineers curious about science-driven innovation._

### How does the new PDL1-targeting cancer therapy also act as a vaccine

After degrading PDL1 on a tumor cell, the same molecule delivers a fragment of a common virus that the immune system already recognizes, causing nearby immune cells to attack the tagged cancer cell. This combines tumor defense suppression and immune targeting in a single treatment that activates only inside the tumor. It was tested with four doses every three days in mice and in lab-grown patient tumor tissue, but not yet in human trials.

_Readers tracking cross-disciplinary innovation follow biotech breakthroughs like this on daily.dev._

## Similar posts on daily.dev

- [A new approach to cancer vaccination yields more powerful T cells](https://daily.dev/posts/a-new-approach-to-cancer-vaccination-yields-more-powerful-t-cells-cpohvm6nf) · MIT News · 0 upvotes · 0 comments
- [Amping up T cells to target cancer](https://daily.dev/posts/amping-up-t-cells-to-target-cancer-9kzgfcilx) · MIT Technology Review · 0 upvotes · 0 comments
- [MIT engineers create nanoparticles for delivering personalized cancer vaccines](https://daily.dev/posts/mit-engineers-create-nanoparticles-for-delivering-personalized-cancer-vaccines-qcjhxqx88) · MIT News · 0 upvotes · 0 comments
- [How CRISPR Could Mark Mutated Cancer Cells For Termination](https://daily.dev/posts/how-crispr-could-mark-mutated-cancer-cells-for-termination-rm8j2aez0) · Hackaday · 0 upvotes · 0 comments
- [Reprogrammed NK immune cells target cancer and autoimmune disorders](https://daily.dev/posts/reprogrammed-nk-immune-cells-target-cancer-and-autoimmune-disorders-ejla5ocwp) · MIT News · 0 upvotes · 0 comments

---

Tags: [#biotech](https://daily.dev/tags/biotech)

[View this post on daily.dev](https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv)

```json
{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://daily.dev/#organization","name":"daily.dev","url":"https://daily.dev","logo":{"@type":"ImageObject","url":"https://daily.dev/apple-touch-icon.png","width":180,"height":180},"sameAs":["https://twitter.com/dailydotdev","https://github.com/dailydotdev","https://www.linkedin.com/company/daily-dev-ltd"]},{"@type":"WebSite","@id":"https://daily.dev/#website","url":"https://daily.dev","name":"daily.dev","publisher":{"@id":"https://daily.dev/#organization"},"potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://daily.dev/search?q={search_term_string}"},"query-input":"required name=search_term_string"}}]}
{"@context":"https://schema.org","@type":"TechArticle","headline":"It’s biotech, but it works almost like programmable software","url":"https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv","mainEntityOfPage":{"@type":"WebPage","@id":"https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv"},"datePublished":"2026-08-28T13:05:43.543Z","dateModified":"2026-09-14T06:43:40.553Z","description":"Researchers at Peking University engineered a bifunctional molecule that both destroys PD-L1 (the protein tumors use to suppress nearby immune cells) and...","image":"https://i.ytimg.com/vi/GgE6hmHsYnM/sddefault.jpg","thumbnailUrl":"https://i.ytimg.com/vi/GgE6hmHsYnM/sddefault.jpg","isAccessibleForFree":true,"articleSection":"Tiff In Tech","inLanguage":"en","publisher":{"@type":"Organization","name":"daily.dev","url":"https://daily.dev","logo":{"@type":"ImageObject","url":"https://daily.dev/apple-touch-icon.png","width":180,"height":180}},"author":{"@type":"Organization","name":"Tiff In Tech","logo":"https://media.daily.dev/image/upload/s--cw-MSz5l--/f_auto/v1724391415/logos/tiffintech","url":"https://daily.dev/sources/tiffintech"},"commentCount":0,"discussionUrl":"https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv","interactionStatistic":[{"@type":"InteractionCounter","interactionType":{"@type":"LikeAction"},"userInteractionCount":0},{"@type":"InteractionCounter","interactionType":{"@type":"CommentAction"},"userInteractionCount":0}],"keywords":"biotech","timeRequired":"PT1M","video":{"@type":"VideoObject","name":"It’s biotech, but it works almost like programmable software","description":"Researchers at Peking University engineered a bifunctional molecule that both destroys PD-L1 (the protein tumors use to suppress nearby immune cells) and...","thumbnailUrl":"https://i.ytimg.com/vi/GgE6hmHsYnM/sddefault.jpg","uploadDate":"2026-08-28T13:05:43.543Z","duration":"PT1M","url":"https://api.daily.dev/r/NUw8IrQzv","embedUrl":"https://www.youtube.com/embed/GgE6hmHsYnM"}}
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://daily.dev"},{"@type":"ListItem","position":2,"name":"Tiff In Tech","item":"https://daily.dev/sources/tiffintech"},{"@type":"ListItem","position":3,"name":"It’s biotech, but it works almost like programmable software"}]}
{"@context":"https://schema.org","@type":"FAQPage","@id":"https://daily.dev/posts/it-s-biotech-but-it-works-almost-like-programmable-software-nuw8irqzv#faq","mainEntity":[{"@type":"Question","name":"What is PDL1 and why do tumors use it to evade the immune system","acceptedAnswer":{"@type":"Answer","text":"PDL1 is a protein displayed on tumor cell surfaces that signals nearby immune cells to stand down, allowing the tumor to avoid attack even as it grows. Researchers at Peking University built a targeted protein degrader designed to find and destroy PDL1, removing that suppressive signal so the immune system can respond. daily.dev surfaces emerging biotech mechanisms like this for engineers curious about science-driven innovation."}},{"@type":"Question","name":"How does the new PDL1-targeting cancer therapy also act as a vaccine","acceptedAnswer":{"@type":"Answer","text":"After degrading PDL1 on a tumor cell, the same molecule delivers a fragment of a common virus that the immune system already recognizes, causing nearby immune cells to attack the tagged cancer cell. This combines tumor defense suppression and immune targeting in a single treatment that activates only inside the tumor. It was tested with four doses every three days in mice and in lab-grown patient tumor tissue, but not yet in human trials. Readers tracking cross-disciplinary innovation follow biotech breakthroughs like this on daily.dev."}}]}
```

